Abstract
Background The potential impact of COVID-19 alongside influenza on morbidity, mortality and health service capacity is a major concern as the Northern Hemisphere winter approaches. This study investigates the interaction between influenza and COVID-19 during the latter part of the 2019-20 influenza season in England.
Methods Individuals tested for influenza and SARS-CoV-2 were extracted from national surveillance systems between 20/01/2020 and 25/04/2020. To estimate influenza infection on the risk of SARS-CoV-2 infection, univariable and multivariable analyses on the odds of SARS-CoV-2 in those who tested positive for influenza compared to those who tested negative for influenza. To assess whether a coinfection was associated with severe SARS-CoV-2 outcome, univariable and multivariable analyses on the odds of death adjusted for age, sex, ethnicity, comorbidity and coinfection status.
Findings The risk of testing positive for SARS-CoV-2 was 58% lower among influenza positive cases, suggesting possible pathogenic competition between the two viruses. Patients with a coinfection had a risk of death of 5.92 (95% CI, 3.21-10.91) times greater than among those with neither influenza nor SARS-CoV-2 and 2.27 (95% CI, 1.23 to 4.19) greater than COVID alone suggesting possible synergistic effects in coinfected individuals. The odds of ventilator use or death and ICU admission or death was greatest among coinfection patients showing strong evidence of an interaction effect compared to SARS-CoV-2/influenza acting independently.
Interpretation Cocirculation of these viruses could have a significant impact on morbidity, mortality and health service demand. Testing for influenza alongside SARS-CoV-2 and maximising influenza vaccine uptake should be prioritised to mitigate these risks.
Funding This study was funded by Public Health England
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding: This study was funded by Public Health England
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This surveillance was performed as part of PHEs responsibility to monitor COVID-19 during the current pandemic. PHE has legal permission, provided by Regulation 3 of The Health Service (Control of Patient Information) Regulations 2002 to collect confidential patient information http://www.legislation.gov.uk/uksi/2002/1438/regulation/3/made under Sections 3(i) (a) to (c), 3(i)(d) (i) and (ii) and 3(3) as part of its outbreak response activities. As such this work falls outside the remit for ethical review. The study protocol was subject to an internal review by the PHE Research Ethics and Governance Group and was found to be fully compliant with all regulatory requirements. As no regulatory issues were identified, and ethical review is not a requirement for this type of work, it was decided that a full ethical review would not be necessary.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This version revised for the following: Amended the odds of testing positive for SARS-CoV-2 was 68% lower among influenza positive cases (OR 0.42, 95% CI 0.31-0.56) to 58% lower in the abstract, results and discussion. Amended of the following sentence in the abstract: Patients with a coinfection had a risk of death of 5.92 (95% CI, 3.21-10.91) times greater than among those with neither influenza nor SARS-CoV-2 and 2.27 (95% CI, 1.23 to 4.19) greater than COVID alone suggesting possible synergistic effects in coinfected individuals. Added the following sentence in the results: Furthermore, patients with a SARS-CoV-2 and influenza coinfection were around 2.3 times (95% CI, 1.23 to 4.19) more likely to die compared to those with SARS-CoV-2 alone.
Data Availability
The SGSS (Second Generation Surveillance System) and DataMart were used to obtain all influenza positive cases. Cases of SARS-CoV-2 and influenza coinfection were matched to the Public Health England COVID-19 deaths dataset. In addition, all cases were linked to the Demographic Batch Service (DBS), a national database coordinated by NHS digital that allows the tracing of information against personal demographics, and the date of death was extracted. Test results were also linked to the Secondary Uses Service (SUS) dataset and the Hospital Episode Statistics dataset, which contain information on all admitted patient care, outpatient and A&E attendances at NHS hospitals in England. All PHE individual-level owned databases used in this study were under Regulation 3 of The Health Service (Control of Patient Information) (Secretary of State for Health, 2002). Availability of this data could lead to identifiable deductive disclosure and therefore is not shared in the public domain. For all other datasets used in this study, links for user permissions can be found here: DBS: http://nww.connectingforhealth.nhs.uk/demographics/dbs/. HES: https://digital.nhs.uk/data-and-information/data-tools-and-services/data-services/hospital-episode-statistics. SUS: https://digital.nhs.uk/services/secondary-uses-service-sus
